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ABSTRAK 
 
POLYMYXIN B SEBAGAI TERAPI JANGKITAN KUMAN GRAM NEGATIF 
YANG RESISTAN TERHADAP PELBAGAI ANTIBIOTIK : HASIL 
PENGGUNAAN DAN FAKTOR RISIKO TERHADAP KEGAGALAN TERAPI DI 
UNIT RAWATAN RAPI 
 
Objektif : Polymyxin adalah salah satu antibiotik yang telah lama diperkenalkan, dan kini 
digunakan kembali setelah sekian lama sebagai terapi infeksi kuman gram negatif, 
disebabkan oleh kurangnya penemuan antibiotik baru pada masa kini. Tujuan penyelidikan 
ini adalah untuk mengkaji hasil terapi dan mencari factor risiko terhadap kegagalan terapi 
polymyxin B di Unit Rawatan Rapi. Hasil terapi yang dilihat adalah kesembuhan secara 
klinikal dan kegagalan secara klinikal. 
 
Metodologi : Kajian ini dijalankan secara ‘crossectional’, menggunakan rekod perubatan, 
dan dilaksanakan di Unit Rawatan Rapi, Hospital Universiti Sains Malaysia. Kajian ini 
melibatkan 96 kes jangkitan kuman gram negatif (jangkitan kuman di dalam darah, dan 
jangkitan paru-paru), di mana kuman penyebabnya adalah  Acinetobacter spp, 
Acinetobacter baumanii, Klebsiella pneumonia and Pseudomonas aeruginosa yang 
diisolasi daripada specimen cecair endotrakea, darah, dan ‘bronchoalveolar lavage’. 
Pemilihan sampel bermula dari senarai pesakit yang mendapat rawatan polymyxin B dari 
data farmasi dari tahun 2010-2014. Sebanyak 96 sample diambil secara rawak dan rekod 
perubatan kes-kes ini dilihat kembali. Data demografik, sejarah penyakit dahulu, 
penggunaan antibiotik, keputusan mikrobiologi dan hasilnya dicatat. 
xii 
 
 
Keputusan : Daripada 96 sampel yang dikaji, sebanyak 51% (49 kes) menunjukkan 
kesembuhan selepas terapi polymyxin, manakala 49% atau 47 kes yang lainnya mengalami 
kegagalan. Kesemua kes kegagalan terapi berakhir dengan kematian, dan semua kematian 
tersebut adalah disebabkan oleh kuman gram negatif. Faktor risiko yang dikenalpasti 
menyebabkan kegagalan berdasarkan analisis ‘Multiple Logistic Regression’ adalah adanya 
jangkitan kuman di dalam darah (p=0.005) dan dos polymyxin yang tidak optimal 
(p=0.005). Polymyxin B dapat ditoleransi dengan baik oleh hampir semua subjek, di mana 
hanya 7 dari 96 sunjek sahaja menunjukkan penurunan fungsi ginjal, walaubagaimanapun 
penurunan fungsi ginjal ini tidak mengakibatkan penggunaan polymyxin B dihentikan. 
 
Kesimpulan : Sebagai kesimpulan, kuman gram negatif yang resistan tehadap pelbagai 
antibiotik mempunyai kadar kematian yang semakin meningkat dan membimbangkan. 
Sensitiviti kuman yang pantas, antibiotik yang sesuai seperti polymyxin B dan diberikan 
dengan kadar segera, juga kombinasi antibiotik seperti sulperazone dapat menjanjikan 
kesembuhan terhadap pesakit-pesakit kritikal. 
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ABSTRACT 
 
POLYMYXIN B THERAPY FOR MULTIDRUG RESISTANT GRAM NEGATIVE 
INFECTIONS : OUTCOME AND RISK FACTORS FOR TREATMENT FAILURE 
IN CRITICAL CARE 
 
Objective: Polymyxins have re-administered in clinical practice due to the dry antibiotic 
development pipeline and worldwide increasing infections caused by multi-drug resistant 
(MDR) gram negative bacteria. The aim of this study is to investigate the use of polymyxin 
B antibiotic therapy in Intensive Care Unit, Hospital Universiti Sains Malaysia (HUSM) 
and to identify the risk factors for polymyxin B treatment failure. Outcomes will be 
classified into clinical cure and clinical failure. 
  
Methodology: This was a  crossectional study using secondary data done in Intensive Care 
Unit (ICU) Hospital Universiti Sains Malaysia, Kubang Kerian, Kelantan. This study 
involved 96 cases of gram negative infections (blood-stream infection and pneumonia),  
particularly Acinetobacter spp, Acinetobacter baumanii, Klebsiella pneumonia and 
Pseudomonas aeruginosa, isolated from blood, endotracheal aspirate (ETA) as well as 
bronchoalveolar lavage (BAL) sample, all were treated with iv polymyxin B. The patient 
selections were from pharmacy databank on polymyxin B usage from 1 January 2010- 
31 December 2014. Ninety-six cases treated with polymyxin B from ICU were randomly 
selected and their medical record were traced from Record Office and reviewed. Their 
xiv 
 
demographic profiles, underlying diseases, potential risk factors, antibiotic usage, possible 
adverse effects, microbiology results and outcome were reviewed. 
 
Results: Clinical outcome was evaluated for the 96 samples. Clinical cure contributed to 
51% of the cases (49 cases) meanwhile another 47 cases (49%) contributed to clinical 
failure. Percentage of clinical cure was slightly higher compared to clinical failure for this 
study. 47 clinical failure subject (49.0%) reported death and all were referred to attributable 
mortality. Associated risk factors for polymyxin B treatment failure by Multiple Logistic 
Regression model were primary bacteremia (p=0.005) and inappropriate dose of polymyxin 
B (p=0.005). Polymyxin B was well tolerated by almost all of our sample, whereby only 7 
out of 96 cases experienced deteriorating renal function, and it was not lead to 
discontinuation of the treatment.. 
 
Conclusions: In conclusion, mortality associated with multidrug resistant gram negative 
pathogens continues to be high. The early susceptibility, prompt and optimal antibiotic such 
as polymyxin B and also combination of antibiotic in particular with sulperazaone seems to 
have a survival benefit in this critically ill population. 
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CHAPTER 1 
 
INTRODUCTION 
 
 
Multidrug-resistant Gram-negative organisms (MDRGNs) have developed as a 
major hazard to hospitalized patients. It have been associated with high mortality rates 
ranging from 30 to 70% (Tamma et al., 2012). Gram-negative bacilli, particularly those 
with a high level of intrinsic resistance to many antibiotic classes and great ability to 
acquire resistance, such as Pseudomonas aeruginosa, Klebsiella pneumonia, and 
Acinetobacter baumannii, cause infections that are extremely difficult to treat (Kwa et 
al., 2008). 
 
Treatment of infections caused by these pathogens also has become considerably 
more challenging. It is due to the stagnation in development of novel antimicrobial 
agents to threat this pathogen. The emergence of these pathogen resistant to almost all 
antibiotics therefore has led to the re-administration of Polymyxins  as “salvage” 
therapy in critically ill patient (Michalopoulos and Falagas, 2008).  
 
Polymyxins were released in the late 1950’s. However, the usage were 
decreased due to the potential toxicity and readily available of less toxic antibiotics. But 
later on, interestingly more clinical reports eventually demonstrated the tolerability, 
safety, and effectiveness of Polymyxins (Zavascki et al., 2007). 
 
2 
 
There are five different types of polymyxins products (polymyxin A through E); 
however, only polymyxin B and polymyxin E (colistin) are used in clinical practice. 
Although polymyxin B and polymyxin E (colistin) have the same mechanism of action 
and the same pattern of resistance, colistin is more commonly used in clinical practice. 
There is also very limited clinical experience with Polymyxin B in the literature 
(Zavascki et al., 2008). 
 
There are few studies investigating the use of polymyxin B for treatment of 
infections caused by MDR Gram-negative bacilli, mostly Acinetobacter spp. and  
Pseudomonas  Aeruginosa. Holloway et al. (2006) reported good results after 
administration of intravenous polymyxin B in 29 critically ill patients with infections 
caused by MDR Acinetobacter baumannii. The observed clinical cure was 76%, 
whereas crude mortality rate was 27%. 
 
Pereira et al. (2007) described clinical features and outcomes of 19 patients 
treated with inhaled polymyxin B. Fourteen of them had nosocomial pneumonia  and 
were concomitantly treated with iv polymyxin B. Pseudomonas  aeruginosa was the 
aetiological agent in 11 of these 14 patients. Nine (64%) of the 14 patients died during 
hospitalization, although 13 (93%) of them were described as having a good clinical 
outcome of the pneumonia. 
 
Dubrovskaya et al. (2013) describes outcomes of patients with CRKP infections 
treated with Polymyxin B monotherapy. Forty patients were included in the analysis. 
Twenty-nine of 40 (73%) patients achieved clinical cure as defined by clinician-
documented improvement in signs and symptoms of infections, and 17/32 (53%) 
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patients with follow-up culture data achieved microbiological cure. The clinical cure 
rate achieved in this retrospective study was 73% of patients with CRKP infections 
treated with polymyxin B monotherapy. 
 
 This study was designed to determine the outcome of polymyxin B therapy 
for multi-drug resistant gram negative organisms and to identify risk factors for the 
treatment failure in critical care unit HUSM. This will help clinicians to gain clear 
picture regarding  the outcome of Polymyxin B treatment and risk factors for treatment 
failure in our  local situation since there are very large variations among regions, 
countries, hospitals and settings. 
 
 It is also hoped that the results will provide knowledge of the general risk 
factors associated with Polymyxin B treatment failure so that it may help avoid and/or 
recognise this complication of therapy at an early stage.  
 
 And finally it is expected that clinician’s awareness regarding the treatment 
failure will be increased because awareness may potentially lead to improve outcomes. 
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CHAPTER 2 
 
LITERATURE REVIEW 
  
 
2.1 Multidrug-Resistant Gram Negative Bacili Infections 
 
 2.1.1 Definition 
 
 For epidemiologic purposes, in literal term, MDR means ‘resistant to more than 
one antimicrobial agent’, but no standardized definitions for MDR have been agreed so 
far (Magiorakos et al., 2012). Many definitions are being used to characterize multidrug 
resistance patterns in gram-positive and gram-negative organisms, however there is still 
absence of specific definitions for MDR in clinical study protocols leads to difficulties 
to compae the data. Nevertheless, group of international experts came together through 
a joint initiative by the European Centre for Disease Prevention and Control (ECDC) 
and the Centers for Disease Control and Prevention (CDC), to create a standardized 
international terminology to describe acquired resistance profiles particularly in 
Stapylococcus aureus, Enterococcus spp, Enterobactericiae (other than Salmonella and 
Shigella), Pseudomonas aeruginosa and Acinetobacter spp. All are bacteria often 
responsible for healthcare-associated  infections and prone to multidrug resistance. 
(Falagas et al., 2006),(Cohen et al., 2008). The experts agreed that three issues need to 
be considered to develop the definitions: (i) how to create antimicrobial ‘categories’ that 
would be epidemiologically meaningful; (ii) how to select the antimicrobial categories 
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and agents to be tested for each relevant bacterium; and (iii) how to define resistance 
within antimicrobial category (Magiorakos et al., 2012). 
 
Finally, the definitions for the characterization of bacterial isolates that are 
MDR, XDR (extensively drug-resistant) or PDR (pandrug-resistant) are proposed and 
given in Table 1. For all three definitions, non-susceptibility refers to either a resistant, 
intermediate or non-susceptible result obtained from in vitro antimicrobial susceptibility 
testing (Magiorakos et al., 2012). 
 
 MDR is defined as non-susceptibility to at least one agent in three or more 
antimicrobial categories,  XDR is defined as non-susceptibility to at least one agent in 
all but two or fewer antimicrobial categories (i.e. bacterial isolates remain susceptible to 
only one or two categories), whereas PDR is defined as non-susceptibility to all agents 
in all antimicrobial categories (i.e. no agents tested as susceptible for that organism). 
 
Table 2.1. Definitions for multidrug-resistant (MDR), extensively drug-resistant 
(XDR) and pandrug-resistant (PDR) Gram-negative bacteria 
 
Bacterium MDR XDR PDR 
Enterobacteriaceae The isolate is non-
susceptible to at least 1 agent 
in ≥ 3 antimicrobial 
categories listed in Table 22 
The isolate is non-
susceptible to at least 1 agent 
in all but 2 or fewer 
antimicrobial categories in 
Table 2.2 
Non-susceptibility to all 
agents in all antimicrobial 
categories for each bacterium 
in Tables 2.2–2.4 
Pseudomonas aeruginosa The isolate is non-
susceptible to at least 1 agent 
in ≥ 3 antimicrobial 
categories listed in Table 2.3 
The isolate is non-
susceptible to at least 1 agent 
in all but 2 or fewer 
antimicrobial categories in 
Table 2.3 
Acinetobacter spp. The isolate is non-
susceptible to at least 1 agent 
in ≥ 3 antimicrobial 
categories listed in Table 2.4 
The isolate is non-
susceptible to at least 1 agent 
in all but 2 or fewer 
antimicrobial categories in 
Table 2.4 
http://www.ecdc.europa.eu/en/activities/diseaseprogrammes/ARHAI/Pages/public_consultation_clinical_microbiology_infect
ion_article.aspx. 
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Table 2.2. Enterobacteriaceae; antimicrobial categories and agents used to define 
MDR, XDR and PDR 
 
Antimicrobial category Antimicrobial agent Species with intrinsic resistance to 
antimicrobial agents or categories 
Aminoglycosides Gentamicin Providencia rettgeri (P. rettgeri), 
Providencia stuartii (P. stuartii) 
Tobramycin P. rettgeri, P. stuartii 
Amikacin  
Netilmicin P. rettgeri, P. stuartii 
Anti-MRSA cephalosporins Ceftaroline (approved only for 
Escherichia coli, Klebsiella 
pneumoniae, Klebsiella oxytoca 
 
Antipseudomonal penicillins 
+ b-lactamase inhibitors 
Ticarcillin-clavulanic acid Escherichia hermannii (E. hermanii 
Piperacillin-tazobactam E. hermanii 
Carbapenems Ertapenem  
Imipenem  
Meropenem  
Doripenem  
Non-extended spectrum cephalosporins; 
1st and 2nd generation cephalosporins 
Cefazolin Citrobacter freundii (C. freundii), 
Enterobacter aerogenes (E. aerogenes), 
Enterobacter cloacae (E. cloacae), 
Hafnia alvei (H. alvei), Morganella 
morganii (M. morganii), Proteus 
penneri (P. penneri), Proteus vulgaris 
(P. vulgaris), P. rettgeri, P. stuartii, 
Serratia marcescens (S. marcescens) 
Cefuroxime M. morganii, P. penneri, P. vulgaris, 
S.marcescens 
Extended-spectrum cephalosporins; 3rd 
and 4th generation cephalosporins 
Cefotaxime or ceftriaxone  
Ceftazidime  
Cefepime  
Cephamycins Cefoxitin C. freundii, E. aerogenes, E. cloacae, 
H. alvei 
Cefotetan C. freundii, E. aerogenes, E. cloacae, 
H. alvei 
Fluoroquinolones Ciprofloxacin  
Folate pathway inhibitors Trimethoprim-sulphamethoxazole  
Glycylcyclines Tigecycline M. morganii, Proteus mirabilis (P. 
mirabilis), 
P. penneri, P. vulgaris, P. rettgeri, P. 
stuartii 
Monobactams Aztreonam  
Penicillins Ampicillin Citrobacter koseri (C. koseri), C. 
freundii, E. aerogenes, E. cloacae, E. 
hermanii, H. alvei, Klebsiellae spp., M. 
morganii, P. penneri, P. vulgaris, P. 
rettgeri, P. stuartii, S. marcescens 
Penicillins + b-lactamase inhibitors Amoxicillin-clavulanic acid C. freundii, E. aerogenes, E. cloacae, 
H. alvei, 
M. morganii, P. rettgeri, P. stuartii, S. 
marcescens 
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Ampicillin-sulbactam C. freundii, C. koseri, E. aerogenes, E. 
cloacae, H. alvei, P. rettgeri, S. 
marcescens 
Phenicols Chloramphenicol  
Phosphonic acids Fosfomycin  
Polymyxins Colistin M. morganii, P. mirabilis, P. penneri, 
P. vulgaris, P. rettgeri, P. stuartii, S. 
marcescens 
Tetracyclines Tetracycline M. morganii, P. mirabilis, P. penneri, 
P. vulgaris, P. rettgeri, P. stuartii 
Doxycycline M. morganii, P. penneri, P. vulgaris, P. 
rettgeri, P. stuartii 
Minocycline M. morganii, P. penneri, P. vulgaris, P. 
rettgeri, P. stuartii 
http://www.ecdc.europa.eu/en/activities/diseaseprogrammes/ARHAI/Pages/public_consultation_clinical_microbiology_infect
ion_article.aspx. 
 
 
 
Table 2.3. Pseudomonas aeruginosa; antimicrobial categories and agents used to 
define MDR, XDR and PDR 
 
Antimicrobial category Antimicrobial agent 
Aminoglycosides Gentamicin 
Tobramycin 
Amikacin 
Netilmicin 
Antipseudomonal carbapenems Imipenem 
Meropenem 
Doripenem 
Antipseudomonal cephalosporins Ceftazidime 
Cefepime 
Antipseudomonal fluoroquinolones Ciprofloxacin 
Levofloxacin 
Antipseudomonal penicillins + b-lactamase inhibitors Ticarcillin-clavulanic acid 
Piperacillin-tazobactam 
Monobactams Aztreonam 
Phosphonic acids Fosfomycin 
Polymyxins Colistin 
Polymyxin B 
http://www.ecdc.europa.eu/en/activities/diseaseprogrammes/ARHAI/Pages/public_consultation_clinical_microbiology_ 
infection_article.aspx. 
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Table 2.4. Acinetobacter spp.; antimicrobial categories and agents used to define 
MDR, XDR and PDR 
 
Antimicrobial category Antimicrobial agent 
Aminoglycosides Gentamicin 
Tobramycin 
Amikacin 
Netilmicin 
Antipseudomonal carbapenems Imipenem 
Meropenem 
Doripenem 
Antipseudomonal fluoroquinolones Ciprofloxacin 
Levofloxacin 
Antipseudomonal penicillins + b-lactamase inhibitors Ticarcillin-clavulanic acid 
Piperacillin-tazobactam 
Extended-spectrum cephalosporins Cefotaxime 
Ceftriaxone 
Ceftazidime 
Cefepime 
Folate pathway inhibitors Trimethoprim-sulphamethoxazole 
Penicillins + b-lactamase inhibitors Ampicillin-sulbactam 
Polymyxins Colistin 
Polymyxin B 
Tetracyclines Tetracycline 
 Doxycycline 
 Minocycline 
http://www.ecdc.europa.eu/en/activities/diseaseprogrammes/ARHAI/Pages/public_consultation_clinical_microbiology_ 
infection_article.aspx. 
 
  
2.1.2 Prevalance 
 
Gram-negative bacilli are the primary cause of serious infections in both the 
community and hospital settings. Resistance to individual antimicrobials rapidly 
increases in gram-negative bacilli (D'Agata, 2004). 
 
Rate of MDR, gram-negative bacilli has been reported in several studies. 
According to one of the studies, the global SENTRY Antimicrobial Surveillance 
Program reported percentage of MDR Pseudomonas aeruginosa in 1997 to 1999 ranged 
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from 0.9% in Canada to 8.2% in Latin America. In this study, MDR was defined as 
resistance to piperacillin, ceftazidime, imipenem, and gentamicin (Gales et al., 2001).  
 
In another study by the Surveillance Network Database–USA, it was  reported 
that rate of MDR Pseudomonas aeruginosa, defined as resistance to at least three of the 
antimicrobials ceftazidime, ciprofloxacin, gentamicin, and imipenem, increased from 
5.5% in 1998 to 7.0% in 2001, among non-ICU patients. The Surveillance Network also 
described that rate of multidrug resistance among members of the family 
Enterobacteriaceae in 2001, ranged from 0.3% for Proteus mirabilis to 3.1% for 
Escherichia coli (Karlowsky et al., 2003). 
 
Meanwhile, a 9-year surveillance study by D'Agata (2004) testified that, a 
significant rise in multidrug resistance, defined as resistance to 3 or more antimicrobial 
classes from 1994 to 2002, was observed among gram-negative bacilli. Among all 
nosocomial isolates, multidrug-resistant Pseudomonas aeruginosa increased from 1% in 
1994 and 1995 to 16% in 2002. Similar rises were noticed for members of the family 
Enterobacteriaceae with rate of multidrug-resistant Klebsiella species, multidrug-
resistant Proteus species, and multidrug-resistant Escherichia coli increased from less 
than 1% in 1994 and 1995 to 17%, 9%, and 4%, respectively, in 2002. The most 
common coresistant antimicrobial pattern among these multidrug-resistant, gram-
negative bacilli included quinolones, third-generation cephalosporins, and 
aminoglycosides. Whereas, ceftazidime was included among multidrug-resistant 
Pseudomonas aeruginosa isolates, in all co-resistant patterns (D'Agata, 2004). 
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2.2 Common organisms 
 
2.2.1 General 
 
 Characteristically, gram-negative bacteria are non-pathogenic in the 
immunocompetent host, especially for the Enterobacteriaceae and the non fermentative 
gram-negative bacilli. However, gram-negative bacteria can become significant 
pathogens in the incapacitated host. The ability to prevent and treat gram-negative 
nosocomial infection is mostly troubled by antimicrobial resistance (Hidron et al., 
2008). 
 
 Due to higher mortality rate associated with these organisms worldwide, three 
common multidrug resistant gram-negative bacilli organisms will be discussed in this 
literature, namely Acinetobacter spp., Klebsiella pneumonia, and Pseudomonas 
aeruginosa. 
 
2.2.2 Acinetobacter spp. 
 2.2.2.1 Background 
 
 Acinetobacter is a gram-negative coccobacillus that has appeared as a vital 
nosocomial pathogen. It is non-motile, encapsulated, and non-fermentative. It belongs 
to the family of Neisseriaceae (Rungruanghiranya et al., 2005). Acinetobacter 
baumannii,  Acinetobacter genomic species 3, and Acinetobacter genomic species 13TU 
are the predominant pathogenic organisms among all the Acinetobacter spp. Practically, 
these species are often grouped together using the term ‘Baumannii group’. They 
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frequently cause persistent outbreaks within and across healthcare facilities, and also are 
proficient in developing resistance to multiple antimicrobial agents (28). 
 
  2.2.2.2  Epidemiology of MDR Acinetobacter spp. 
 
 The incidence of nosocomial infections caused by Acinetobacter spp. has 
increased gradually in recent years worldwide.  
 
 In the UK, extensive outbreaks of carbapenem-resistant Acinetobacter spp. have 
arisen since 2000. A number of different clones were identified affecting multiple health 
care institutions. The rates of non-susceptibility to meropenem rose from 13 to 29% 
between 2004 and 2008. In the meantime, non-susceptibility of Acinetobacter spp. to 
other classes of antimicrobials was reported at: aminoglycosides 20%; ciprofloxacin 
30%; ceftazidime 70%; cefotaxime 89%; piperacillin/ tazobactam 50% in 2008. In 
European countries, the highest resistance rates have been reported in Mediterranean 
regions including Greece, Turkey, Italy and Spain (Coelho et al., 2006).  
 
Likewise in the US, data on healthcare-associated infections showed that 65-
75% of Acinetobacter spp. isolates were multi-drug resistant, and that carbapenem non-
susceptibility rose from 9% in 1995 to 57% in 2008 (Hoffmann et al., 2010). Figures 
from Ireland on Acinetobacter is somewhat limited. A university hospital in Ireland 
identified 114 Acinetobacter spp. isolated from clinical specimens over a 30 month 
period between 2005 and 2007. Automated methods recognized 77 as A. baumannii, 
however with molecular methods, the major species was actually A. genomic species 3. 
Out of 114 isolates, 11% were carbapenem resistant (Boo et al., 2009).  
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 2.2.2.3  Clinical Significance 
 
It is observed that Ventilator-associated pneumonia (VAP) is the most common 
infection due to Acinetobacter.  Rates of VAP due to Acinetobacter approach 5-10% in 
some countries. Acinetobacter species are known causes of infection in patients with 
surgical sites, burn, wounds, and lately have been recognised in infections complicating 
injured military personnel. Acinetobacter species cause BSIs in minority in the United 
Kingdom and in the United States. Nevertheless, crude mortality figures attribute to 
Acinetobacter infection differ considerably ranging from 34-67%. This is due to 
inadequate empirical therapy when managing infections. Colonisation and infection 
have also been independently associated with higher morbidity, costs and prolonged 
hospitalisation (Garnacho-Montero et al., 2005). 
 
 2.2.2.4  Laboratory Detection 
 
Acinetobacter species grow well routinely on standard culture media. They can 
be identified at the genus level (Gram-negative, catalase-positive, oxidase negative and 
non-fermenting coccobacilli). Accurate subspeciation remains challenging and lengthy. 
Automated methods are often unable to distinguish between the three species of clinical 
significance. Furthermore, phenotypic methods to identify mechanisms of resistance are 
unreliable. Hence, there has been a growing use of molecular methods both for 
speciation, and for detection of particular resistance gene determinants. Such methods 
are also important for epidemiological purposes in an outbreak setting (28). 
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2.2.3 Klebsiella pneumonia 
 
 2.2.3.1 Background 
 
 Klebsiella pneumoniae is a gram-negative bacilli that normally live in the 
gastrointestinal tract. There is a term used to define this group of organism, called 
Enterobacteriaceae. Other organisms include in Enterobacteriaceae group are  
Escherichia coli, , Enterobacter cloacae, and Citrobacter freundii. β-lactams are a 
group of antimicrobials that contain some of the most frequently used antibiotics (such 
as penicillins, cephalosporins, monobactams and carbapenems) for treating infections. 
The main mechanism for the development of resistance to the various types of β-lactam 
antimicrobials is the production of enzymes, known as b-lactamases by 
Enterobacteriaceae. Nowadays, lots of  b-lactamases exist, including extended spectrum 
b-lactamases (ESBL), AmpC b-lactamases and carbapenemases. These enzymes have 
multiple ranges of hydrolytic activity and are usually located on mobile genetic 
elements, known as plasmids, that can enhance their transmission ability (Bradford, 
2001). 
 
 
 2.2.3.2 Epidemiology 
 
Carbapenem resistance, caused by the combination of ESBL/AmpC production 
and porin loss, has been reported for several years. Although resistant strains can be 
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transmitted between patients, this resistance mechanism cannot be transferred to other 
bacterial strains (28). 
 
Carbapenemases are a different group of broad spectrum b-lactamases. The most 
common encountered carbapenemases are: 
 Klebsiella pneumoniae carbapenemase (KPC) 
 New Delhi metallo-b-lactamase (NDM) 
 Verona Integron-encoded metallo-β-lactamase (VIM) 
 Oxacillinase (OXA) 
 
The most worrying part is the rapid international dissemination of 
carbapenemases, as illustrated by the importation of NDM-1 from the Indian 
subcontinent to the United Kingdom and other European countries as well as the global 
importation of KPC from the United States to various continents. The fast spread of 
these carbapenemases is usually facilitated by transfer of plasmids between strains or 
species and/or clonal dissemination of certain strains (Nordmann et al., 2009; 
Kumarasamy et al., 2010). 
 
In Europe, Greece is considered endemic for CRE. Significant problems of CRE 
dissemination have also been reported in other European countries such as Italy, Poland, 
France, Spain and the UK (Nordmann et al., 2009; Kumarasamy et al., 2010). 
 
Although mainly found in patients from the UK, NDM-1-producing 
Enterobacteriaceae have also been reported in other European countries such as 
Germany, France and Scandinavian countries. OXA-48 has been reported in various 
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regions including the India, Europe, Middle East, and North Africa (Grundmann et al., 
2010). 
 
First data on carbapenem resistance among K. pneumoniae isolates were stated 
from EARSS/ EARS-NET in 2005, when Greece already reported 28% carbapenem 
resistance. Greece reported 49% carbapenem resistance among K. pneumoniae isolates 
in 2010. Importantly in 2010 , Italy’s resistance rate increased from 1.3% in 2009 to 
15%. 
 
CRE have also been encountered in Irish healthcare centers since 2009. While 
only sporadic cases had been described in 2009 and 2010, the epidemiology of CRE 
changed significantly in Ireland in 2011. Throughout 2011, CRE was reported from 36 
patients in eight Irish hospitals, with four hospitals reporting CRE outbreaks. In January 
2011, an outbreak with KPC producing K. pneumoniae was reported in the mid-west, 
with documented interhospital spread. An outbreak of OXA-48 K. pneumoniae occurred 
in a tertiary hospital in Dublin during spring 2011. Other hospitals have also reported 
intermittent cases of KPC-, OXA-48-, and VIM-producing K. pneumoniae  as well as 
VIM-producing E. cloacae (Boo et al., 2009). The first incident of NDM-1 producing 
K. pneumoniae discovered in Ireland was notified in summer 2011. In June 2011, a 
monthly prevalence survey was conducted in 40 Irish critical care units. Patients were 
screened weekly for rectal carriage of carbapenemase-producing CRE. CRE was not 
detected in any of the 40 participants during this study (Prior et al., 2010; O’Brien et al., 
2011).  
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 2.2.3.3 Clinical Significance 
 
Members of the Enterobacteriaceae group frequently cause bacterial infections 
in all ages patients. The most common sites of infection are UTI, intra-abdominal 
sepsis, surgical site infections and BSI (28). 
 
There are less therapeutic options for the treatment of infections caused by 
resistant Enterobacteriaceae. This is because of these organisms are often resistant to 
other classes of antimicrobials such as aminoglycosides and fluoroquinolones. At 
present, carbapenems are the treatment of choice for infections caused by ESBL-
producing and AmpC-hyperproducing organisms. However it is afraid that the reliance 
to carbapenems will lead to the emergence of carbapenem resistance (Bradford, 2001).  
 
Most Enterobacteriaceae producing carbapenemases are resistant to 
carbapenems in vivo . Therefore therapeutic options for CRE infection are very limited. 
The resistance profiles of most strains leave only a few antimicrobial agents available as 
potential therapeutic options for example tigecycline, fosfomycin and colistin. 
However, non-susceptibility or resistance to these antimicrobials is also  reported 
progressively in CRE (Nordmann et al., 2009; Kumarasamy et al., 2010). Some CRE 
strains may have carbapenem minimum inhibitory concentrations (MICs) that fall 
within the susceptible range according to CLSI or EUCAST breakpoint criteria. Yet, the 
clinical significance of carbapenemases in such strains is still unclear. Infections caused 
by resistant Enterobacteriaceae are associated with increase risk of mortality. Mortality 
rates associated with infections caused by CRE ranged from 38-57% (Boo et al., 2009). 
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 2.2.3.4 Laboratory Detection 
 
Optimal laboratory detection of resistant Enterobacteriaceae from speciments is 
essential for therapeutic decisions as well as for timely and effective implementation of 
infection control measures. As therapeutic options can be very limited, (particularly in 
the case of CRE), it is recommended that every effort should be undertaken by 
laboratories to identify resistant Enterobacteriaceae (28). 
 
In some laboratories, carbapenem susceptibility testing may not be regularly 
performed in Enterobacteriaceae isolates from certain clinical samples, mainly urine 
specimens. Remarkably, a significant proportion of isolates from patients with CRE 
were from urine specimens. A European working group has recently recommended 
susceptibility testing of Enterobacteriaceae from all anatomical sites with at least one 
carbapenem (Grundmann et al., 2010). Most carbapenemase-producing 
Enterobacteriaceae are similarly resistant to cephalosporins. The potential pitfall of 
using cephalosporin (such as cefpodoxime) as a substitute indicator for carbapenem 
resistance is the failure to detect OXA-48-producing strains, which can be susceptible to 
cephalosporins unless co-producing ESBLs (Nordmann et al., 2009; Kumarasamy et al., 
2010). 
 
Several phenotypic tests have been described for the detection of carbapenemase 
production in Enterobacteriaceae. Two most frequently used methods are the modified 
Hodge test (MHT) and inhibitor-based synergy tests.. These phenotypic tests can be 
used by laboratories to further analyse organisms with elevated carbapenem MICs for 
potential carbapenemase production. As none of the above phenotypic methods have 
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universally accepted interpretive standards, the use of molecular methods such as end-
point or real-time PCR for the detection of carbapenemase genes has been 
recommended for isolates suspected of carbapenemase production (Miriagou et al., 
2010). 
   
 
2.2.4 Pseudomonas aeruginosa 
 
 2.2.4.1 Background 
 
Pseudomonas aeruginosa is a Gram-negative bacteria existing widely in the 
environment, present in diverse environmental settings (e.g. aquatic environments and 
soil) and is also known to colonise plants, animals and humans. P. aeruginosa is mainly 
termed as an opportunistic pathogen causing disease in compromised hosts, for example 
immunocompromised patients, patients in intensive care settings, and patients with 
chronic lung disease (28). 
 
 2.2.4.2 Epidemiology 
 
P. aeruginosa represents a considerably important nosocomial pathogen. Due to 
the high prevalence of infection, increasing rates of antimicrobial non-susceptibility and 
the worrying characteristic of the emergence of resistance during therapy further 
interrupt efforts to successfully control infections due to this pathogen. Non-
susceptibility rates of P. aeruginosa to many classes of antimicrobials have stayed 
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largely stable across Europe and the US; however a worrying trend of increasing non-
susceptibility to carbapenems has been observed worldwide (28). 
 
The frequency of MDR P. aeruginosa amongst BSI isolates in Europe in 2010, 
was estimated to be 15%. The highest rates of MDR P. aeruginosa were reported from 
Greece (42.5%), and the Czech Republic (29%). This remains highest in Southern and 
Eastern European states. Overall 16 of 28 countries reported that 10% or more of the P. 
aeruginosa isolates were resistant to carbapenems. Countries with the highest non-
susceptibility to these agents include Cyprus (29%), Bulgaria (31%) and Greece (43%), 
(28). 
 
Data from BSI surveillance in the UK between 2001 and 2006 reported that 2.5 - 
4% of all BSI isolates were P. aeruginosa. Non-susceptibility rates remained broadly 
stable with the exception of carbapenems. Non-susceptibility to meropenem increased 
from 5.7% to 10%. Isolates from an ICU setting showed statistically higher rates of 
non-susceptibility to imipenem and piperacillin/tazobactam. US estimates of MDR 
amongst P. aeruginosa raised at 18% in 2000, 21% in 2003, and most recently 17% in 
2008 (28).  
 
 2.2.4.3 Clinical Significance 
 
P. aeruginosa is the second most common cause of healthcare-associated 
pneumonia in the US, causing 14-16% of cases (30).  European surveillance data for 
ICUs showed P. aeruginosa as the causative pathogen for 23-30% of cases of VAP, 
19% of UTI and 10% of BSI. Equivalent figures from ICUs in the US are VAP 21%, 
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UTI 10%, and BSI 3% respectively. Infection due to MDR P. aeruginosa is associated 
with increased morbidity and mortality, prolonged length of stay, and increased costs. In 
particular, inappropriate empirical therapy in the context of MDR infection has been 
independently associated with both prolonged bacteraemia and higher morbidity and 
mortality (Hoffmann et al., 2010). 
 
 2.2.4.4 Laboratory Detection 
 
P. aeruginosa is easily isolated and identified in the laboratory. Antimicrobial 
resistance can be measured using standard disc diffusion or commercial automated 
methods. Molecular methods have been used to identify specific resistance mechanisms. 
By benefit of the relative impermeability of its outer membrane, P. aeruginosa is 
intrinsically resistant to many antimicrobials. Moreover, multiple separate resistance 
mechanisms have been identified, which combined contribute to the resistant 
phenotypes observed in clinical settings. The mechanisms may be inherent to the 
bacterium or acquired via mobile genetic elements/plasmids (28). 
 
 
 
2.3 Frequent types of infection caused by MDR GN Infections 
 
The gram-negative bacilli differ in the frequencies that they cause the 4 most 
common types of hospital-acquired infection: bloodstream infection (BSI), pneumonia, 
surgical site infection (SSI), and urinary tract infection (UTI) (Weinstein et al., 2005). 
During the past 20 years, changes in health care, infection-control practices, and 
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antimicrobial use and resistance may have influenced the frequency that these gram-
negative organisms are associated with hospital-acquired infection. 
 
In this literature, all the 4 types of infections will be discussed including 
definition and criteria for diagnosing based on CDC/NHSN Surveillance Definition of 
Healthcare-Associated Infection and Criteria for Specific Types of Infections in the 
Acute Care Setting. However in this study only 2 types of the infection are included, 
namely BSI and pneumonia. 
 
 2.3.1 Blood Stream Infection 
 
Primary bloodstream infection includes laboratory-confirmed bloodstream 
infection and clinical sepsis. The definition of clinical sepsis is intended primarily for 
infants and neonates (Garner et al., 1988; Horan et al., 2008). 
 
Laboratory-confirmed bloodstream infection must meet one of the following 
criteria: 
a. Recognized pathogen isolated from blood culture AND pathogen is not 
related to infection at another site. 
b.  One of the following: fever (>38
o
 C), chills, or hypotension AND any of 
the following: 
i.  Common skin contaminantt isolated from two blood cultures 
drawn on separate occasions AND organism is not related to 
infection at another site. 
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ii.  Common skin contaminant isolated from blood culture from 
patient with intravascular access device AND physician institutes 
appropriate antimicrobial therapy. 
iii.  Positive antigen test on blood AND organism is not related to 
infection at another site. 
c.  Patient <12 months of ages has one of the following: fever (>38
o
 C), 
hypothermia (<37
o
 C), apnea, or bradycardia AND any of the following: 
i.  Common skin contaminant isolated from two blood cultures 
drawn on separate occasions AND organism is not related to 
infection at another site. 
ii.  Common skin contaminant isolated from two blood cultures 
drawn on separate occasion and organism is not related to 
infection at another site. 
iii. Positive antigen test on blood and pathogen is not related to 
infection at another site. 
Clinical sepsis must meet either of the following criteria: 
a.  One of the following clinical signs or symptoms with no other 
recognized cause: fever (>38
o
 C),  hypotension (systolic pressure <90 
mm Hg), or oliguria (<20 ml/hr) AND all of the following: 
i.  Blood culture not done or no organism or antigen detected in 
blood. 
ii.  No apparent infection at another site. 
iii.  Physician institutes appropriate antimicrobial therapy for sepsis. 
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b.  Patient <12 months of age has one of the following clinical signs or 
symptoms with no other recognized cause: fever (>38
o
 C), hypothermia 
(<37
o
 C), apnea, or bradycardia AND all of the following: 
i.  Blood culture not done or no organism or antigen detected in 
blood. 
ii.  No apparent infection at another site. 
iii.  Physician institutes appropriate antimicrobial therapy for sepsis. 
 
 When an organism isolated from blood culture is compatible with a related 
nosocomial infection at another site, the bloodstream infection is classified as a 
secondary bloodstream infection.  Exceptions to this are intravascular device-associated 
bloodstream infections, all of which are classified as primary even if localized signs of 
infection are present at the access site (Garner et al., 1988; Horan et al., 2008). 
 
 
 2.3.2 Pneumonia 
 
Pneumonia is defined separately from other infections of the lower respiratory 
tract. The criteria for pneumonia involve various combinations of clinical, radiographic, 
and laboratory evidence of infection. In general, expectorated sputum cultures are not 
useful in diagnosing pneumonia but may help identify the etiologic agent and provide 
useful antimicrobial susceptibility data. Findings from serial chest x-ray studies may be 
more helpful than those from a single x-ray film (Garner et al., 1988; Horan et al., 
2008). 
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Pneumonia must meet one of the following criteria: 
a.  Rales or dullness to percussion on physical examination of chest AND 
any of the following: 
i.  New onset of purulent sputum or change in character of sputum. 
ii.  Organism isolated from blood culture. 
iii.  Isolation of pathogen from specimen obtained by transtracheal 
aspirate, bronchial brushing, or biopsy. 
b.  Chest radiographic examination shows new or progressive infiltrate, 
consolidation, cavitation, or pleural effusion AND any of the following: 
i.  New onset of purulent sputum or change in character of sputum. 
ii.  Organism isolated from blood culture. 
iii.  Isolation of pathogen from specimen obtained by transtracheal 
aspirate, bronchial brushing, or biopsy. 
iv.  Isolation of virus or detection of viral antigen in respiratory 
secretions. 
v.  Diagnostic single antibody titer (IgM) or fourfold increase in 
paired serum samples (IgG) for pathogen. 
vi.  Histopathologic evidence of pneumonia. 
c.  Patient <12 months of age has two of the following: apnea, tachypnea, 
bradycardia, wheezing, rhonchi, or cough AND any of the following: 
i. Increased production of respiratory secretions.  
ii. New onset of purulent sputum or change in character of sputum. 
iii. Organism isolated from blood culture. 
iv. Isolation of pathogen from specimen obtained by transtracheal 
aspirate, bronchial brushing, or biopsy. 
